NasdaqGM:FOLDBiotechs
Amicus Therapeutics (FOLD) Rides DMX-200 Progress and Bullish Coverage – Is Its Pipeline Undervalued?
In recent days, Dimerix announced that its ACTION3 Phase 3 trial of DMX-200 for focal segmental glomerulosclerosis completed recruitment and dosing of 286 adult patients, while Amicus Therapeutics drew fresh attention after new analyst coverage highlighted the company’s earnings potential.
Together, the late-stage progress of DMX-200 and the wave of optimistic research coverage sharpen the focus on Amicus’s pipeline depth and prospects for earnings improvement.
Now we’ll examine how this...